The UK and US have reached a significant bilateral deal that will guarantee zero duties on UK pharmaceutical exports being sold in the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to boost funding on medicines through the National Health Service (NHS). This pledge secures that tariffs on these key products will stay at nothing for a duration of three years.
This deal comes after earlier warnings to significantly raise duties on patented pharmaceutical products, with potential rates discussed reaching double the cost.
"This agreement with the United Kingdom strengthens the global environment for new treatments and brings long-overdue balance to American-British pharmaceutical trade," an announcement noted.
Commercial Importance
Medicines constitute one of the UK's most significant goods shipped to the US, which is easily the largest destination for leading UK drugmakers.
Export figures reveal that in the year to the end of September, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This figure made up nearly one-fifth of total UK exports in that span.
"This agreement protects employment, increases investment and paves the way for the UK to become a global hub for life sciences," the Business and Trade Secretary commented.
Key British Pledges
The agreement includes several specific commitments from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a target to increase total health service expenditure on drugs from 0.3% of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to stay within budget will be limited at fifteen percent. Previously, refunds exceeded twenty percent.
Recent Tensions
This agreement follows a ongoing row between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
These tensions were intensified by claims that US patients were paying a premium for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been delayed or scrapped, while substantial funding commitments have been pledged toward American operations.
The Science Minister acknowledged that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the previous ten-year period.
